Hemab Therapeutics Holdings, Inc. Common Stock (COAG)

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.7B; returns 1 day -1.2%, 1 week +14.4%.

Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG) is a clinical-stage biotechnology company specialized in developing subcutaneous prophylactic therapies for rare and underserved blood coagulation disorders. As of May 2026, the company generates no revenue, with operations funded by a significant $346.7 million upsized IPO completed in early May 2026 and a $157 million Series C round in late 2025.

Groups COAG belongs to

• Biotechnology
• Clinical Stage
• Recent IPOs
• Hematology
• Biopharmaceutical
• Rare Diseases
• Bispecific Antibodies
• Life Sciences
• Healthcare
• Antibody Therapeutics
• Unmet Medical Needs
• Clinical Stage Biotech

COAG financial model: income statement, cash flow and balance sheet